Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure.
about
Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy.CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxelPharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.Germline pharmacogenetics of paclitaxel for cancer treatment.Breath tests to phenotype drug disposition in oncology.
P2860
Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure.
@ast
Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure.
@en
type
label
Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure.
@ast
Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure.
@en
prefLabel
Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure.
@ast
Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure.
@en
P2093
P2860
P1476
Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure.
@en
P2093
Arlene S Bridges
Christine M Walko
Daniel L Hertz
E Claire Dees
J Heyward Hull
Jill Herendeen
Kristan Rollins
Paul B Watkins
P2860
P304
P356
10.1111/J.1365-2125.2012.04165.X
P407
P577
2012-07-01T00:00:00Z